Jury Awards $382 Million in Damages RANCHO SANTA MARGARITA, Calif.–(BUSINESS WIRE)–Applied Medical announced today a significant legal victory that should help Jury Awards $382 Million in Damages RANCHO SANTA MARGARITA, Calif.–(BUSINESS WIRE)–Applied Medical announced today a significant legal victory that should help

Applied Medical Prevails in Antitrust Jury Trial Against Medtronic

2026/02/06 08:15
2 min read

Jury Awards $382 Million in Damages

RANCHO SANTA MARGARITA, Calif.–(BUSINESS WIRE)–Applied Medical announced today a significant legal victory that should help open the healthcare market to innovation and lower costs. A U.S. District Court jury unanimously found Medtronic, Inc. liable for violations of federal and state antitrust laws and awarded $381,705,005 in damages.

Applied Medical, represented by Knobbe Martens, filed the case in February 2023, alleging that Medtronic engaged in exclusionary unlawful bundling and exclusive dealing practices to suppress competition in the market for advanced bipolar vessel sealing devices.

After a 10-day trial in Los Angeles, the jury found that Medtronic violated the Sherman Act, the Clayton Act, and the California Cartwright Act through its use of restrictive contracts with healthcare providers. Following this verdict, Applied Medical intends to seek injunctive relief to prohibit Medtronic from enforcing these unlawful restrictions.

“We are profoundly grateful to the jury for their time, their attention to the evidence, and their decisive verdict,” said Gary Johnson, group president advanced energy, who represented Applied Medical throughout the trial. “This is not just a legal victory for Applied; it is a validation of fair competition. We believe this decision marks a turning point for hospitals and healthcare providers struggling to dismantle complex contractual barriers that have long prevented them from access to innovation, choice and value.”

About Applied Medical

Applied Medical is dedicated to providing innovative solutions that enhance patient outcomes and enable the advancement of minimally invasive surgery. As a new generation medical device company, Applied Medical is committed to having a significant and sustainable impact on healthcare by delivering breakthrough technologies that enhance clinical care and satisfy the pressing economic needs of its customers. As a vertically integrated organization, Applied Medical manufactures its products in-house at its corporate headquarters in Southern California. Applied Medical is proud to provide its products and unique business model to customers in more than 75 countries. To learn more, visit AppliedMedical.com.

Contacts

Media Contact: Kimberly Cashion, kcashion@appliedmedical.com

Market Opportunity
Union Logo
Union Price(U)
$0.001582
$0.001582$0.001582
+1.93%
USD
Union (U) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Cashing In On University Patents Means Giving Up On Our Innovation Future

Cashing In On University Patents Means Giving Up On Our Innovation Future

The post Cashing In On University Patents Means Giving Up On Our Innovation Future appeared on BitcoinEthereumNews.com. “It’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress,” writes Pipes. Getty Images Washington is addicted to taxing success. Now, Commerce Secretary Howard Lutnick is floating a plan to skim half the patent earnings from inventions developed at universities with federal funding. It’s being sold as a way to shore up programs like Social Security. In reality, it’s a raid on American innovation that would deliver pennies to the Treasury while kneecapping the very engine of our economic and medical progress. Yes, taxpayer dollars support early-stage research. But the real payoff comes later—in the jobs created, cures discovered, and industries launched when universities and private industry turn those discoveries into real products. By comparison, the sums at stake in patent licensing are trivial. Universities collectively earn only about $3.6 billion annually in patent income—less than the federal government spends on Social Security in a single day. Even confiscating half would barely register against a $6 trillion federal budget. And yet the damage from such a policy would be anything but trivial. The true return on taxpayer investment isn’t in licensing checks sent to Washington, but in the downstream economic activity that federally supported research unleashes. Thanks to the bipartisan Bayh-Dole Act of 1980, universities and private industry have powerful incentives to translate early-stage discoveries into real-world products. Before Bayh-Dole, the government hoarded patents from federally funded research, and fewer than 5% were ever licensed. Once universities could own and license their own inventions, innovation exploded. The result has been one of the best returns on investment in government history. Since 1996, university research has added nearly $2 trillion to U.S. industrial output, supported 6.5 million jobs, and launched more than 19,000 startups. Those companies pay…
Share
BitcoinEthereumNews2025/09/18 03:26
China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise

The post China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise appeared on BitcoinEthereumNews.com. China Blocks Nvidia’s RTX Pro 6000D as Local Chips Rise China’s internet regulator has ordered the country’s biggest technology firms, including Alibaba and ByteDance, to stop purchasing Nvidia’s RTX Pro 6000D GPUs. According to the Financial Times, the move shuts down the last major channel for mass supplies of American chips to the Chinese market. Why Beijing Halted Nvidia Purchases Chinese companies had planned to buy tens of thousands of RTX Pro 6000D accelerators and had already begun testing them in servers. But regulators intervened, halting the purchases and signaling stricter controls than earlier measures placed on Nvidia’s H20 chip. Image: Nvidia An audit compared Huawei and Cambricon processors, along with chips developed by Alibaba and Baidu, against Nvidia’s export-approved products. Regulators concluded that Chinese chips had reached performance levels comparable to the restricted U.S. models. This assessment pushed authorities to advise firms to rely more heavily on domestic processors, further tightening Nvidia’s already limited position in China. China’s Drive Toward Tech Independence The decision highlights Beijing’s focus on import substitution — developing self-sufficient chip production to reduce reliance on U.S. supplies. “The signal is now clear: all attention is focused on building a domestic ecosystem,” said a representative of a leading Chinese tech company. Nvidia had unveiled the RTX Pro 6000D in July 2025 during CEO Jensen Huang’s visit to Beijing, in an attempt to keep a foothold in China after Washington restricted exports of its most advanced chips. But momentum is shifting. Industry sources told the Financial Times that Chinese manufacturers plan to triple AI chip production next year to meet growing demand. They believe “domestic supply will now be sufficient without Nvidia.” What It Means for the Future With Huawei, Cambricon, Alibaba, and Baidu stepping up, China is positioning itself for long-term technological independence. Nvidia, meanwhile, faces…
Share
BitcoinEthereumNews2025/09/18 01:37
Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver Price Crash Is Over “For Real This Time,” Analyst Predicts a Surge Back Above $90

Silver has been taking a beating lately, and the Silver price hasn’t exactly been acting like a safe haven. After running up into the highs, the whole move reversed
Share
Captainaltcoin2026/02/07 03:15